Answers are grounded in this paper and cite their sources.
Research into the role of the human epidermal receptor growth factor receptor 1/epidermal growth factor receptor (HER1/EGFR) in tumorigenesis has generated a new class of anticancer drugs. One such agent, erlotinib (Tarceva), is a potent, selective and reversible inhibitor of HER1/EGFR tyrosine kinase activity. Erlotinib has demonstrated the clinical activity in a variety of solid tumors, and has recently demonstrated improvements in survival in large Phase III trials, in non-small-cell lung cancer and pancreatic cancer.
No takes yet. Share an insight, caveat, or question.
Giuseppe Giaccone (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: